

Case Report

Peripheral Giant Cell Granuloma in Pregnancy: A Case Report

Francisco Javier Alcaraz Baturoni ¹, José Sergio Zepeda Nuño ², Brenda Fernanda Nolasco González ³ ,
Moisés Ramos Solano ⁴ , Melissa Martínez Nieto ¹ and Sarah Monserrat Lomelí Martínez ^{1,5,6,7,*} 

- ¹ Periodontics Program, Department of Integral Dentistry Clinics, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; francisco.alcaraz@academicos.udg.mx (F.J.A.B.)
- ² Microbiology and Pathology Department, Pathology Laboratory, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; jsergio.zepeda@academicos.udg.mx
- ³ Independent Researcher, Guadalajara 44340, Jalisco, Mexico; fernanda_gonzaleznb@hotmail.com
- ⁴ Instituto de Investigación en Cáncer de la Infancia y la Adolescencia (INICIA), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico; biolog.moises@gmail.com
- ⁵ Department of Medical and Life Sciences, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán 47810, Jalisco, Mexico
- ⁶ Master of Public Health Program, Department of Wellbeing and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlán 46200, Jalisco, Mexico
- ⁷ Prosthodontics Program, Department of Integral Dentistry Clinics, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
- * Correspondence: sarah.lomeli@academicos.udg.mx

Abstract: Peripheral giant cell granuloma (PGCG) is an asymptomatic, non-neoplastic, and proliferative lesion of unknown etiology. Possible pre-disposing factors, such as hormonal changes during pregnancy, have been suggested. However, the association between PGCG and pregnancy is controversial. There are few reported clinical cases of pregnancy-associated PGCG in the literature, and they occurred only in the lower jaw. The present report is on a 35-year-old female patient at 36 weeks of gestation who presented with a PGCG in the central and lateral incisors of the upper jaw. Management consisted of complete surgical excision of the lesion along with a margin of healthy tissue under local anesthesia, followed by curettage of the adjacent fibers of the affected bony wall. The patient experienced adequate healing without complications. The diagnosis of PGCG was based on clinical characteristics, imaging examinations, and histopathological confirmation. The patient underwent postoperative follow-up evaluations at 3, 6, and 12 months, and there were no signs of recurrence.

Keywords: peripheral giant-cell granuloma; giant-cell epulis; giant-cell hyperplasia; case report



Citation: Alcaraz Baturoni, F.J.; Zepeda Nuño, J.S.; Nolasco González, B.F.; Ramos Solano, M.; Martínez Nieto, M.; Lomelí Martínez, S.M. Peripheral Giant Cell Granuloma in Pregnancy: A Case Report. *Appl. Sci.* **2023**, *13*, 12688. <https://doi.org/10.3390/app132312688>

Academic Editor: Tommaso Lombardi

Received: 11 November 2023
Revised: 24 November 2023
Accepted: 25 November 2023
Published: 27 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Peripheral giant cell granuloma (PGCG) is the most common oral giant cell lesion. It appears as an extraosseous soft tissue nodule that originates from the connective tissue of the periosteum or the periodontal ligament membrane, and is localized within the soft tissues [1–4]. This pathology is identified by other names, such as giant cell reparative granuloma, osteoclastoma, giant cell epulis, and giant cell hyperplasia of the oral mucosa [5].

The lesion has a predilection for the buccal gingiva rather than the lingual or palatal. It occurs more frequently in the lower jaw rather than the upper jaw, especially in the incisors and canines [3,6]. It is often located in the interdental papilla, edentulous alveolar ridge, or marginal gingiva in completely or partially edentulous patients, resulting in gingival contour changes that can cause tooth mobility and displacement [3,4,7]. It is more frequent in women than in men, with a 2:1 incidence ratio, and the incidence is higher in the age group of 30–50 years [3,5,6,8]. While rare, it may occur in pediatric patients

as well [3,5]. In most cases, PGCG is asymptomatic; however, the presence of the lesion can be bothersome when it interferes with occlusion or is associated with an infectious or ulcerative process [3–5]. The size of the lesion may vary from a small papule to a massive enlargement which does not typically exceed a diameter of 5 cm [3]. In certain cases, progressive growth may lead to significant tumors that compromise speech, chewing, or swallowing, with evolution time ranging from three months to four years [3,4].

PGCG develops extraosseously; however, in edentulous areas, a cup-shaped superficial erosion of the underlying bone may be noted, termed bone flattening or “saucerization”. However, in dentate areas widening of the periodontal ligament space, destruction of the alveolar crest, and tooth displacement may be noted [3,4].

Although the etiology of PGCG remains uncertain, it may be related to various factors, including trauma, inflammatory foci, nutritional impact, maladjusted restorations, overextended fillings, occlusal trauma, genetic predisposition, dental calculus, and the use of orthodontic appliances [3,5,9]. Additionally, hormonal changes during pregnancy have been considered a possible contributing factor. However, due to the limited number of clinical cases described in the literature, the association between PGCG and pregnancy remains controversial [10–12]. The objective of this study was to describe the surgical management of a clinical case of upper jaw PGCG associated with pregnancy.

2. Case Report

A 35-year-old female patient presented with an increase in volume in her gum near the upper lip that caused difficulty in chewing and complicated oral hygiene in that particular area. The patient was systemically healthy and was not taking drugs at the time. Medical and family histories did not reveal any abnormalities. The patient stated that the growth appeared during the 36th week of gestation. However, she refrained from seeking dental care until a week before terminating her pregnancy due to concerns about the impact of anesthetic dental procedures on her baby. We spoke with her and cleared her doubts regarding the risks of dental care while emphasizing the importance of identifying an injury in its early stages. No significant findings were detected in the extra-oral examination.

Intraoral clinical examination identified an increase in the volume of the gum (measuring 1.0 cm × 0.7 cm × 0.3 cm) located between the central and upper left lateral incisors, and partially filling the vestibular space. On palpation, the area presented a soft consistency, a rough texture, an oval base with slight mobility, and a pink coloration with irregular margins but without bleeding or pain (Figure 1). Furthermore, a probing depth of 9 mm was recorded vestibularly. Subgingival calculus and plaque were present. Contradictorily, there were no signs of dental mobility and the patient referred no symptomatology. Intra-oral peri-apical radiograph revealed no pathological findings or any signs of bone loss, root resorption, or increased periodontal ligament space (Figure 2). A complete blood count was performed and all blood results were within normal limits. Based on the information obtained from the historical, clinical, and radiographic examinations, a presumptive diagnosis of pyogenic granuloma or PGCG was considered.

The patient received oral health education as well as scaling and root planing during the initial phase of treatment. Complete excision with a surgical blade and curettage of the lesion were planned for therapy. The patient authorized an Informed Consent Statement in compliance with NOM-004-SSA3-2012 in the clinical file and articles 21–24 of the Regulation of the General Law of Health in Research Matters (RLGSMI) in Mexico as well as the guidelines set by the Council for International Organizations of Medical Sciences (CIOMS). Local infiltration anesthesia was used on the buccal area. The treatment consisted of removing the lesion with blade No. 15c angulated 45 degrees to the coronal plane using the conventional technique, which required the involvement of 1 mm of surrounding healthy tissue followed by curettage of the adjacent fibers. Additionally, a slight milling of the alveolar bone was performed to remove irritating factors. Oral prophylaxis was performed using an ultrasonic device and Gracey 1–2 curettes to eliminate local irritants on the adjacent teeth. The implemented suturing technique consisted of simple interrupted

stitches using 6-0 nylon; the choice of this suture material was due to its ease of handling, biocompatibility, and minimal tissue reaction. Postoperative instructions were provided at the end, and a new appointment was made to remove the sutures (Figure 3). The obtained sample was fixed in 10% formalin prior to routine histopathological examination (Figure 4).




Figure 1. Preoperative clinical view of PGCG in the patient, showing an increase in gum volume corresponding to the circumscribed and well delimited lesion between maxillary central and lateral incisors. (A) Frontal view; (B) lateral view.



Figure 2. Periapical radiograph of the affected dental organs without the presence of bone disease.




Figure 3. Postoperative clinical view. (A) Frontal view; (B) lateral view.



Figure 4. Excised tissue samples for histopathological examination.

Histological analysis showed proliferation of granulation tissue (Figure 5). The benign enlargement consisted of numerous vascular and lymphatic spaces of different calibers (white arrow), some of which were congestive hemosiderin deposits, moderately diffuse and mixed inflammatory infiltrates comprising plasma cells, lymphocytes, histiocytes, and polymorphonuclear cells, as well as multi-nucleated osteoclast-type giant cells (yellow arrow) containing two or more than ten nuclei. Several of these cells had pyknotic nuclei, with stroma containing abundant collagen fibers arranged in a lax and irregular manner. Additionally, in certain areas multiple spindle cells and presence of reactive bone tissue were recognized. The covering epithelium was of the stratified squamous para-keratinized type, which exhibited loss of continuity, with deposits of eosinophilic material compatible with fibrin (black arrow). These characteristics corroborated the presumptive diagnosis of peripheral giant cell granuloma. Follow-up evaluations at 3, 6 and 12 months were implemented, during which satisfactory clinical conditions were observed without recurrence.




Figure 5. Histopathological examination of the excised specimen showing proliferation of multi-nucleated giant cells in the cell matrix. Magnification: (A) $\times 10$. Vascular and lymphatic spaces of different calibers (white arrow), deposits of eosinophilic material compatible with fibrin (black arrow); (B) $\times 20$. Multi-nucleated osteoclast-type giant cells (yellow arrow).

3. Discussion

Peripheral giant cell granuloma (PGCG) is an exophytic, extra-osseous, and non-neoplastic pathology that originates in the periosteum or periodontal ligament [1]. The etiology of PGCG is unknown; however, hormones have been considered as contributing factors, although this association is controversial. Few clinical cases of pregnancy-associated

PGCG have been described [10–12]. This study presents a case of pregnancy-associated PGCG in the upper jaw.

The complexity of the etiology of GPCG involves several hypotheses of reactive processes, the nature of multinucleated giant cells, and the influence of cytokines and differentiation factors [1,4,13–15]. GPCG is generally considered a reactive lesion, which means that it is probably triggered by external factors such as the presence of local irritants such as dental biofilm, dental calculus, overflowing restorations, indiscriminate use of toothpicks, chronic infections, food, and tooth impaction [1,4,13–15]. One theory of the nature of the multinucleated giant cells in GPCG proposes that they are osteoclasts, possibly residual from physiological tooth resorption or in reaction to injury to the periosteum; evidence supporting this includes the presence of receptors for calcitonin in these cells and their ability to excavate bone *in vitro* [4]. On the other hand, studies suggest that the giant cells in the GPCG could represent a reactive component derived from bone marrow mononuclear cells in response to an unknown stimulus from the stromal tissue [4]. Recently, research has shown that stromal cells in GPCG secrete various cytokines and differentiation factors. These factors are believed to stimulate the migration of monocytes into the tumor tissue and promote the fusion of these cells into multinucleated osteoclast-like giant cells [4,13]. The imbalance in the Receptor Activator of Nuclear Factor κ B Ligand (RANKL)/Receptor Activator of Nuclear Factor κ B (RANK)/osteoprotegerin (OPG) system could be a contributing factor in the development of GPCG. Alteration in the balance between RANKL and OPG, either by an increase in RANKL or a decrease in OPG, could lead to increased differentiation and activity of osteoclasts and potentially to the formation of multinucleated giant cells [4]. However, it is important to recognize that the etiology of GPCG is multifactorial, and this last mechanism is only one of the possible factors involved.

The roles played by sex hormones in pregnancy in relation to the initiation, development, and progression of PGCG are controversial. During pregnancy, hormonal changes, particularly those involving estrogen and progesterone, promote alterations in the oral cavity. These alterations encompass physiological, vascular, microbiological, and cellular changes, creating a favorable environment for the initiation and development of various pathologies [16–23]. Among the physiological changes that significantly contribute to the prevalence of oral lesions, especially in gingival tissue, are an approximate 1500 mL increase in blood volume (normal volume in women being 4 to 4.5 L), establishing a framework clinical diagnosis for physiological anemia, which can stimulate gingival bleeding and the possible increase in blood glucose levels due to the decrease in sensitivity to insulin by pregnancy hormones, potentially generating a decrease in the elasticity and increase in the permeability of blood capillaries [16,22]. Alterations in the microcirculatory system during pregnancy involve swelling of endothelial cells, increased adhesion of platelets and leukocytes to vessel walls, microthrombi formation, changes in perivascular mast cells, increased vascular permeability, and vascular proliferation [16,22]. Estrogen and progesterone, in conjunction with inflammatory mediators, can induce changes in vascular responses and connective tissue turnover in the periodontium, leading to a higher prevalence of inflammatory processes during hormonal fluctuations [22]. Hormones during pregnancy can induce an increase in Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF), which are activators of angiogenesis, altering the vascular response. VEGF is particularly important, as it acts as a mitogenic factor for endothelial cells, triggering neovascularization within granulomas, and thereby contributing to their appearance and growth. Additionally, other vascular factors such as connective tissue growth factor, angiopoietin-1, angiopoietin-2, Tie-2, ephrinB2, ephrinB4, and decorin have been reported to be involved in profound inflammation and angiogenesis in granulomas. Therefore, the set of these factors, stimulated or modulated by pregnancy hormones, could facilitate the formation of peripheral giant cell granulomas by promoting a proinflammatory and proangiogenic environment in the oral cavity. The oral microbiota undergo changes during pregnancy, in particular an increase in populations of aerobic and anaerobic bacteria such as *Porphyromonas gingivalis*, *Bacteroides melaninogenicus*, and *Prevotella intermedia* [16,19]. These

bacteria affect target cells such as keratinocytes and fibroblasts. Cellular changes in the gingival epithelium are characterized by decreased keratinization, an increase in glycogen content, proliferation of fibroblasts, blockage of collagen degradation, and an increase in the rate of oral mucosa desquamation, favoring bacterial proliferation and resulting in oral lesions [19]. These changes lead to alterations in the epithelial barrier, resulting in heightened responses to irritants, especially in the dental biofilm [18]. Additionally, there is a decrease in the antimicrobial activity of peripheral neutrophils, which are essential components of the innate immune defenses of periodontal tissues. Furthermore, in the oral cavity there is a decrease in pH and a consequent reduction in salivary buffer capacity during pregnancy. Combined with modifications or alterations in eating habits and oral care practices, this increases the risk of microorganism growth and the development of oral lesions [16]. These conditions generated by hormonal changes during pregnancy favor the prevalence and/or severity of certain conditions in the oral cavity [22]. This effect is particularly noticeable after the second month, as it is precisely at this point that there are increases in plasma levels of estrogen and progesterone [16,21]. In their clinical case description of PGCG associated with pregnancy, Caillouette and Mattar (1978) reported that high levels of estrogens and gonadotropic hormones increase the deposition of glycogen in the epithelium and exert a positive trophic effect on the buccal mucosa [10]. These changes lead to hyperplasia of the papillae and blood vessels, resulting in increased vascularity, which in turn favors the development of PGCG. The surgical management of this clinical case involved the extraction of three teeth from the lower jaw to facilitate tumor removal. Additionally, the lesion extended to the mandibular canal, necessitating the sacrifice of the inferior alveolar nerve. In contrast, in the present case no dental organ or nerve sacrifice was necessary for PGCG removal. Subsequently, Csillag et al. (1997) described a clinical case of GCG removal from the mandible which required the extraction of the second molar associated with the lesion. The authors suggested that hormonal and hemodynamic changes during pregnancy may act as stimulating factors for GCG. On the other hand, Patil et al. (2018) reported a clinical case involving the surgical removal of a PGCG in a patient who manifested the lesion during the last trimester of pregnancy. The patient presented generalized gingival inflammation, bleeding on probing, and calculus during clinical examination. Additionally, radiographic examination identified bone resorption in the molar region. In the present case report, no alterations were observed in the soft or hard tissues of the oral cavity. In a descriptive study involving 26 patients with PGCG, Günhan (1998) identified the presence of estrogen and progesterone receptors using the immuno-peroxidase technique [23]. Estrogen receptor positivity was found in stromal cells in fourteen patients, and in ten of these patients the osteoclast-like giant cells exhibited estrogen receptor immunostaining. Based on these results, it was concluded that the cells forming the peripheral giant cell granuloma might be potential targets for estrogens and that the lesion might be influenced by hormonal conditions. In contrast, Shirani (2008) carried out a descriptive study in 20 patients to determine the relationship between PGCG and circulating levels of sex hormones (testosterone, estrogen, and progesterone) [24]. However, no significant association was found between PGCG and sex hormones, and it was concluded that PGCG does not directly depend on testosterone, estrogen, and progesterone studies [25]. Therefore, it was suggested that the role of sex hormones in the development of PGCG might be secondary to local factors such as trauma and poor oral hygiene. In the clinical case described here, we believe that the changes in the oral cavity caused by hormones during pregnancy may be considered as factors that contribute to the onset and progression of PGCG, as no other local triggering conditions for this lesion were present. However, further studies are needed to clarify this association.

Generally, PGCGs occur in soft tissue without affecting the bone, as was observed in the present study, which is consistent with findings from other studies [13,26]. However, giant cells may be activated as an inflammatory response, making them participate as osteoclasts and leading to the resorption of alveolar bone [3]. Osteoclastic activity may be associated with exuberant stromal cell proliferation and bone remodeling [21]. Resorptive

functions may be modulated by estrogen receptors on osteoclasts. On the other hand, the proliferation of osteoclasts in the pathology may be related to other factors.

The treatment of choice for PGCG is surgical excision, as implemented in the present clinical case and in previous studies [1,7,14,27]. This surgical removal method involves excising the lesion along with extensive curettage of the periosteum at the base of the lesion. The associated teeth do not need to be extracted if they are healthy. In fact, it has even been suggested that extraction is contraindicated [2,27]. In addition, it is advisable to remove local irritants. Various treatment modalities have been suggested for PGCG, including intralesional steroids, subcutaneous or nasal calcitonin, subcutaneous injections of alpha-interferon, and the protein tyrosine kinase inhibitor imatinib. However, there is insufficient evidence to support the efficacy of these methods [27]. Using a CO₂ laser or laser resection is another viable treatment option for granuloma removal [27]. The CO₂ laser provides advantages, including reduced bleeding risk and superior coagulation properties. However, it may not be suitable when the lesion affects adjacent bone, in which case thorough surgical curettage becomes necessary [27]. In a study by Chaparro (2005), PGCG excision and biopsy was performed via CO₂ laser in an operation involving two cases and with a cold scalpel in three cases [15]. Laser resection is a technique that allows wound sterilization, causes less intraoperative bleeding, does not require sutures, and provides greater postoperative comfort. However, if the resection is superficial, the condition may reoccur [2]. The surgical modality followed by curettage was implemented in the present case because the lesion involved adjacent bone and because adding curettage reduces the risk of recurrence compared to excision alone.

The recurrence rate of PGCG varies widely [28,29]. Chrcanovic (2018) analyzed 2824 reported cases of PGCG lesions in the literature and found that the overall recurrence rate after treatment was 9.5% [6]. The analysis revealed that when PGCG was treated solely with surgical excision, the recurrence rate was 16%. However, when surgical excision was followed with curettage, the chance of recurrence was reduced by 85% relative to excision alone. Interestingly, other factors such as age, lesion size, duration of follow-up, gender, location of lesion, clinical symptoms, and bone erosion did not appear to influence the probability of recurrence. Additionally, recurrence is associated with not eliminating local irritating factors adjacent to the site where the injury developed, such as hard deposits, food impact, ill-fitting dentures, overhanging restorations, etc. [3,12].

Healthcare professionals need to be aware of the potential impact of pregnancy-associated hormones on the oral cavity. Dentists should be vigilant in monitoring oral lesions during prenatal care. Managing PGCG in any trimester of pregnancy requires a multidisciplinary approach involving dental professionals, obstetricians, and other healthcare providers. Collaboration among specialists ensures the formulation of a safe and effective treatment plan that considers the unique challenges posed by pregnancy [28]. Having a patient-centered approach that addresses her concerns is essential for optimizing treatment outcomes and overall patient satisfaction. Providing reassurance and addressing any anxiety or concerns regarding dental treatment during pregnancy lead to better patient compliance and outcomes [29]. Additionally, it is important to inform pregnant patients that the use of local anesthesia during surgery is safe and does not pose a significant risk to the fetus [30]. Regarding surgical management in pregnant women with PGCG, there are no special considerations; however, it is suggested that in this patient group the use of 2% lidocaine with epinephrine 1:200,000 is the anesthetic agent that best balances safety and effectiveness [22]. Semisupine positioning, blood pressure monitoring, and reassurance are recommended for high-risk mothers in order to reduce the risk of transient changes in blood pressure, hypoxemia, and hypoglycemia [22]. In patients with underlying conditions, such as eclampsia, hypertension, hypotension, and gestational diabetes, dentists should use epinephrine with caution and monitor the anesthetic dose [19]. Implementing oral care recommendations for pregnant women is essential for aiding the prevention and early detection of developing oral lesions. These recommendations include promoting good oral

hygiene practices [30–33], scheduling regular dental check-ups [33], maintaining a balanced diet [34], and implementing monitoring and follow-up when lesions are observed [35].

Finally, future research should aim to evaluate the association between circulating levels of estrogen and progesterone in various trimesters of pregnancy and the presence of PGCG. This research would help to clarify the controversial link between hormonal changes during pregnancy and this condition. Additionally, further studies are needed to investigate the benefits of the various treatment modalities employed for PGCG.

4. Conclusions

This case report highlights the intricate interaction between pregnancy and the development of PGCG, underscoring the importance of early recognition and management of oral pathologies during pregnancy. Despite the relative rarity of PGCG, hormonal changes and alterations in the immune response during pregnancy may predispose pregnant women to this condition. Early identification and accurate diagnosis of this type of pathology are crucial to initiating appropriate treatment and preventing possible complications. This case highlights the success of surgical excision and the need for continued monitoring for recurrence, providing a valuable reference for dental professionals in the treatment of similar conditions.

Author Contributions: Conceptualization, F.J.A.B. and S.M.L.M.; methodology, J.S.Z.N.; formal analysis, F.J.A.B.; investigation, M.R.S. and M.M.N.; data curation, F.J.A.B., B.F.N.G. and M.M.N.; writing—original draft preparation, F.J.A.B., S.M.L.M. and B.F.N.G.; writing—review and editing, J.S.Z.N., M.M.N. and M.R.S.; visualization, S.M.L.M.; supervision, F.J.A.B. and S.M.L.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki. The patient authorized an Informed Consent Statement according to NOM-004-SSA3-2012 of the clinical file and articles 21-24 of the Regulation of the General Law of Health in Research Matters (RLGSMI) in Mexico and the Council for International Organizations of Medical Sciences CIOMS. The confidentiality of the participant's information will be maintained in accordance with the Federal Law on the Protection of Personal Data Held by Obligated Entities.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent was obtained from the patient(s) to publish this paper.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wu, Y.H.; Wu, Y.C.; Lee, Y.P.; Chiang, C.P. Peripheral giant cell granuloma—Case report. *J. Dent. Sci.* **2022**, *17*, 1434–1436. [[CrossRef](#)] [[PubMed](#)]
2. Balaji, P.; Balaji, S.M. Central giant cell granuloma—A case report. *Indian J. Dent. Res.* **2019**, *30*, 130–132. [[PubMed](#)]
3. Cristino, B.A.; Cruz, B.; Borges, A.; Aldape, B. Granuloma periférico de células gigantes: Revisión de 87 casos. *Revista ADM* **2016**, *73*, 175–182.
4. Vasconcelos, R.G.; Vasconcelos, M.G.; Queiroz, L.M.G. Peripheral and central giant cell lesions: Etiology, origin of giant cells, diagnosis and treatment. *J. Bras. Patol. Med. Lab.* **2013**, *49*, 446–452. [[CrossRef](#)]
5. Shadman, N.; Ebrahimi, S.F.; Jafari, S.; Eslami, M. Peripheral giant cell granuloma: A review of 123 cases. *Dent. Res. J.* **2009**, *6*, 47–50.
6. Chrcanovic, B.R.; Gomes, C.C. Peripheral giant cell granuloma: An updated analysis of 2824 cases reported in the literature. *J. Oral Pathol. Med.* **2018**, *47*, 454–459. [[CrossRef](#)]
7. Sharma, N.; Rana, S.; Jetley, S. Peripheral giant cell granuloma of maxilla. *J. Indian Soc. Periodontol.* **2022**, *26*, 75–78. [[CrossRef](#)]
8. Curtis, N.J.; Walker, D.M. A case of aggressive multiple metachronous central giant cell granulomas of the jaws: Differential diagnosis and management options. *Int. J. Oral Maxillofac. Surg.* **2005**, *34*, 806–808. [[CrossRef](#)]
9. Jerkins, D.; Malotky, M.; Miremadi, R.; Dole, M. Central Giant cell granuloma of the mandible requiring multiple treatment modalities: A case report. *J. Oral Maxillofac. Surg.* **2016**, *74*, 1596–1607. [[CrossRef](#)]

10. Caillouette, J.C.; Mattar, N. Massive peripheral giant-cell reparative granuloma of the jaw: A pregnancy dependent tumor. *Am. J. Obstet. Gynecol.* **1978**, *131*, 176–179. [[CrossRef](#)]
11. Csillag, A.; Pharoah, M.; Gullane, P.; Mancser, K.; Disney, T.V. A central giant cell granuloma influenced by pregnancy. *Dentomaxillofac. Radiol.* **1997**, *26*, 357–360. [[CrossRef](#)] [[PubMed](#)]
12. Patil, C.L.; Gaikwad, R.P.; Banodkar, A.B.; Attar, N.B.; Sethna, G.D. Peripheral giant cell granuloma manifestation in pregnancy. *Indian J. Dent. Res.* **2018**, *29*, 678–682. [[CrossRef](#)]
13. Falaschini, S.; Ciavarella, D.; Mazzanti, R.; Di Cosola, M.; Turco, M.; Escudero, N.; Bascones, A.; Lo Muzio, L. Peripheral giant cell granuloma: Immunohistochemical analysis of different markers: Study of three cases. *Av. Odontostomatol.* **2007**, *23*, 189–196.
14. Alarcón, A.; MUÑOZ, R.M.; Schnettler, K.; Ulloa, M.C. Granuloma periférico de células gigantes e hiperparatiroidismo; presentación de un caso. *Int. J. Odontostomatol.* **2019**, *13*, 266–270. [[CrossRef](#)]
15. Chaparro Avendaño, A.V.; Berini Aytés, L.; Gay Escoda, C. Granuloma periférico de células gigantes: A propósito de 5 casos y revisión de la literatura. *Med. Oral Patol. Oral Cirugía Bucal* **2005**, *10*, 41–47.
16. Silva de Araujo, F.C.; Gonçalves, C.R.C.; Costa, C.A.L.; Abreu, F.T.; Fontoura, N.C. Systemic alterations and their oral manifestations in pregnant women. *J. Obstet. Gynaecol. Res.* **2017**, *43*, 16–22. [[CrossRef](#)] [[PubMed](#)]
17. Wiener, R.C.; Wiener-Pla, R. Literacy, pregnancy and potential oral health changes: The Internet and readability levels. *Matern. Child Health J.* **2014**, *3*, 657–662. [[CrossRef](#)] [[PubMed](#)]
18. Naruishi, K. Biological Roles of Fibroblasts in Periodontal Diseases. *Cells* **2022**, *11*, 3345. [[CrossRef](#)]
19. Jang, H.; Patoine, A.; Wu, T.T.; Castillo, D.A.; Xiao, J. Oral microflora and pregnancy: A systematic review and meta-analysis. *Sci. Rep.* **2021**, *11*, 16870. [[CrossRef](#)]
20. Liu, P.P.; Wen, W.; Yu, K.F.; Gao, X.; Wong, M.C.M. Dental Care-Seeking and Information Acquisition During Pregnancy: A Qualitative Study. *Int. J. Environ. Res. Public Health* **2019**, *16*, 2621. [[CrossRef](#)]
21. Cardoso, J.A.; Spanemberg, J.C.; Cherubini, K.; Figueiredo, M.A.; Salum, F.G. Oral granuloma gravidarum: A retrospective study of 41 cases in Southern Brazil. *J. Appl. Oral Sci.* **2013**, *21*, 215–218. [[CrossRef](#)] [[PubMed](#)]
22. Zhou, X.; Zhong, Y.; Pan, Z.; Zhang, J.; Pan, J. Physiology of pregnancy and oral local anesthesia considerations. *PeerJ* **2023**, *29*, e15585. [[CrossRef](#)] [[PubMed](#)]
23. Günhan, M.; Günhan, O.; Celasun, B.; Mutlu, M.; Bostanci, H. Estrogen and progesterone receptors in the peripheral giant cell granulomas of the oral cavity. *J. Oral Sci.* **1998**, *40*, 57–60. [[CrossRef](#)] [[PubMed](#)]
24. Shirani, G.; Arshad, M. Relationship between circulating levels of sex hormones and peripheral giant cell granuloma. *Acta Med. Iran* **2008**, *46*, 429–433.
25. Oliva, L.; De Oliva, M.; Herrera, N.; Andrade, R. Giant cell peripheral granuloma: Post-surgical recurrence. Literature review and clinical case report. *Rev. Odontológica Mex.* **2014**, *18*, 180–185. [[CrossRef](#)]
26. Tandon, P.N.; Gupta, S.K.; Gupta, D.S.; Jurel, S.K.; Saraswat, A. Peripheral giant cell granuloma. *Contemp. Clin. Dent.* **2012**, *3*, 118–121. [[CrossRef](#)]
27. Lindenmüller, I.H.; Noll, P.; Mameghani, T.; Walter, C. CO₂ laser-assisted treatment of a giant pyogenic granuloma of the gingiva. *Int. J. Dent. Hyg.* **2010**, *8*, 249–252. [[CrossRef](#)]
28. Boffano, P.; Gallesio, C.; Barreca, A.; Bianchi, F.A.; Garzino-Demo, P. Granuloma periférico de células gigantes de la cavidad oral: Una revisión sistemática. *Med. Oral Patol. Oral Cirugía Bucal* **2021**, *26*, e244–e253.
29. Greenwall, L.H.; Greene, J.C.; Sirois, D. *Maintaining and Improving the Oral Health of Young Children*; American Academy of Pediatric Dentistry: Chicago, IL, USA, 2014.
30. Reddy, V.S.; Madhiredy, M.; Surapaneni, S.; Kotha, S.B.; Prasad, L.K.; Reddy, B.S. Peripheral Giant Cell Granuloma in Pregnancy: A Case Report and Review of Literature. *J. Orofac. Sci.* **2014**, *6*, 119–122.
31. Neville, B.W.; Damm, D.D.; Allen, C.M.; Chi, A.C. *Oral and Maxillofacial Pathology*, 4th ed.; Elsevier: Amsterdam, The Netherlands, 2016.
32. Alawi, F. Peripheral giant cell granuloma: A review of 123 cases. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **2008**, *105*, 14–21.
33. Jain, N.; Rathore, A.S.; Singh, A.; Agarwal, R.; Meena, B. Peripheral giant cell granuloma: A review of 123 cases. *Natl. J. Maxillofac. Surg.* **2019**, *10*, 50–54.
34. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 462: Moderate caffeine consumption during pregnancy. *Obstet. Gynecol.* **2010**, *116*, 1000–1008.
35. Stomaci, D.; Poti, S.A.; Mariano, F.; Monaco, A. Peripheral Giant Cell Granuloma: A Review of the Literature and Report of a Case. *Open Dent. J.* **2017**, *11*, 163–171.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.